Isofol will be present at the Nordic Life Science Days 2026 in Stockholm
Public source
Publisher name
Public post
Isofol will be present at the Nordic Life Science Days 2026 during this week! Looking forward to fruitful interactions and partnering meetings in Stockholm. https://nlsd…
Company
Isofol
Arfolitixorin - a new drug candidate for the treatment of colorectal cancer – one of the most common types of cancer.
- Industry
- Pharmaceutical Manufacturing
- Location
- Gothenburg, SE
- Company size
- 11–50 employees
About Isofol
Isofol is a publicly listed biotech company developing the drug candidate arfolitixorin to enhance the efficacy of standard treatment for patients with severe forms of cancer. Our goal is s to have a central impact on tomorrow’s cancer treatment, giving more patients the opportunity to respond better to their treatment, improve their prognosis, and gain more time with life. Isofol’s share is listed on Nasdaq Stockholm.
See moreDiscover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
Adragos Pharma
Adragos Pharma Business Development Manager Sofiane will attend NLSDays 2026 on 8 to 9 September at the Nordic Life Science Conference in Stockholm.
Presence & Recognition
Vicore Pharma AB
Vicore Pharma AB is attending the Wells Fargo Healthcare Conference in Boston on September 8, 2026.
Presence & Recognition
Symbiosis Pharmaceutical Services
Symbiosis Pharmaceutical Services is attending Nordic Life Science Days 2026 in Stockholm.
Presence & Recognition
KLIFO
KLIFO is attending NLS Days 2026 in Stockholm on 8 and 9 September.
Presence & Recognition
Disruptive Pharma